MicrosoftTeams-image (93)

RoslinCT & Lykan Bioscience Combine to Create Leading Advanced Cell Therapy CDMO

The RoslinCT-Lykan combination creates an innovative advanced therapies contract development and manufacturing organization (CDMO) with process and analytical development laboratories and cGMP manufacturing facilities located in Hopkinton, Massachusetts and Edinburgh, Scotland.

The combined group will offer process development expertise and cGMP manufacturing for a broad range of autologous and allogeneic cell therapies, with unparalleled expertise in gene editing and industry-leading induced Pluripotent Stem Cell (iPSC) capabilities.


What the RoslinCT-Lykan Combination Offers

  • Expanded Transatlantic Footprint in the US and the UK
  • Extensive capabilities in global cGMP cell therapy/ATMP manufacturing solutions for clinical and commercial
  • Advanced SC, iPSC, and gene editing platform along with other cell platforms such as NK andTIL
  • Process and analytical development expertise across a broad range of autologous and allogeneic cell therapies
  • Deep scientific expertise in the CGT field with a proven record in the delivery of cell-based products.
  • Expanded network in CGT space and flexibility to provide additional support across both companies

Peter Coleman

CEO of RoslinCT

“This combination puts us in a strong position as a leading global CDMO in the process development and manufacturing of advanced cell therapies, and we look forward to working with our new colleagues at Lykan to fuel future growth and meet the increasing demand for innovative therapies”


Patrick Lucy

President and CEO Lykan Bioscience

“We are delighted to combine with RoslinCT to better serve the growing demand for manufacturing capacity and expand the range of innovative services we can provide our partners to support thedevelopment of advanced cell and gene therapies.”


The Partners

at GHO Capital

“This is a significant step towards the realisation of our shared ambition for RoslinCT and Lykan to build a leading global CDMO in the development and manufacture of advanced cell therapies. The collaboration represents an important step in the continued growth and internationalisation of the two businesses and we look forward to partnering with the combined Management teams and WindRose Health Investors to realise this vision.”


CJ Burnes

Partner at WindRose Health Investors

“Lykan has grown tremendously during our ownership, including completion of their state-of-the art facility and the subsequent doubling of cGMP manufacturing capacity. The combination of RoslinCT and Lykan will further accelerate this growth as it creates a unique platform providing key value-added services to the highly complex segment of advanced cell therapies and we look forward to partnering with GHO, RoslinCT and Lykan Management through this next phase.”


About Lykan

Lykan Bioscience is an innovative contract development and manufacturing services organization (CDMO) focused on cell-based therapies. With decades of biopharmaceutical industry experience, Lykan offers a full range of development and manufacturing services. The state-of-the-art, purpose-built facility offering eight independent manufacturing suites is uniquely designed to fully integrate cGMP principles and advanced software solutions to enable real-time testing and release of products.

With the current expansion plan, it will be 16 cGMP suites by the end of 2022 supporting both US and EU clinical and commercial production. Located in Hopkinton, Massachusetts, 25 miles southwest of downtown Boston and in the proximity of four international airports, Lykan Bioscience is ideally situated to deliver life-saving cell therapy treatments to patients on behalf of their partners.


About RoslinCT

Established in 2006 in Edinburgh, Scotland, with support from Scottish Enterprise, RoslinCT was formed through an initial spin-out from the Roslin Institute, which has a famous track record in genetic and cellular biology. Since 2014, the company has had a manufacturing base within the

University of Edinburgh’s Centre for Regenerative Medicine in a facility shared with the Scottish National Blood Transfusion Service. RoslinCT has worked to advance the field of regenerative medicine and today is at the forefront of high-quality cell therapy development and manufacturing. The company recently expanded into facilities at the Edinburgh BioQuarter and is recognized globally as a unique CDMO establishing its own commercial-scale production


Business Development Inquiries